INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Wall Street Zen

INmune Bio (NASDAQ:INMB) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings cut shares of INmune Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, INmune Bio presently has a consensus rating of “Moderate Buy”.

INmune Bio Stock Performance

INMB opened at $2.08 on Friday. The company has a market cap of $55.42 million, a price-to-earnings ratio of -3.11 and a beta of 0.97. The stock has a fifty day simple moving average of $1.63 and a two-hundred day simple moving average of $1.48. INmune Bio has a 12-month low of $1.09 and a 12-month high of $2.61.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, August 6th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.16.

Hedge Funds Weigh In On INmune Bio

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in INmune Bio by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock valued at $1,814,000 after purchasing an additional 28,541 shares in the last quarter. Geode Capital Management LLC raised its holdings in INmune Bio by 6.9% in the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock worth $901,000 after buying an additional 25,069 shares during the last quarter. State Street Corp lifted its stake in shares of INmune Bio by 22.3% in the fourth quarter. State Street Corp now owns 347,259 shares of the company’s stock worth $542,000 after buying an additional 63,426 shares in the last quarter. BlackRock Inc. bought a new position in shares of INmune Bio in the second quarter worth approximately $508,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of INmune Bio during the second quarter valued at approximately $134,000. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.